- Home
- MODD vs ADVM Comparison
MODD vs ADVM Comparison
Compare MODD & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- ADVM
- Stock Information
- Founded
- MODD 1998
- ADVM 2006
- Country
- MODD United States
- ADVM United States
- Employees
- MODD N/A
- ADVM N/A
- Industry
- MODD Industrial Specialties
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MODD Health Care
- ADVM Health Care
- Exchange
- MODD Nasdaq
- ADVM Nasdaq
- Market Cap
- MODD 55.3M
- ADVM 59.5M
- IPO Year
- MODD N/A
- ADVM 2014
- Fundamental
- Price
- MODD $1.00
- ADVM $2.81
- Analyst Decision
- MODD
- ADVM Strong Buy
- Analyst Count
- MODD 0
- ADVM 5
- Target Price
- MODD N/A
- ADVM $26.60
- AVG Volume (30 Days)
- MODD 95.0K
- ADVM 517.4K
- Earning Date
- MODD 06-20-2025
- ADVM 05-20-2025
- Dividend Yield
- MODD N/A
- ADVM N/A
- EPS Growth
- MODD N/A
- ADVM N/A
- EPS
- MODD N/A
- ADVM N/A
- Revenue
- MODD N/A
- ADVM $1,000,000.00
- Revenue This Year
- MODD N/A
- ADVM N/A
- Revenue Next Year
- MODD N/A
- ADVM $42.58
- P/E Ratio
- MODD N/A
- ADVM N/A
- Revenue Growth
- MODD N/A
- ADVM N/A
- 52 Week Low
- MODD $0.68
- ADVM $2.64
- 52 Week High
- MODD $2.65
- ADVM $10.84
- Technical
- Relative Strength Index (RSI)
- MODD 52.36
- ADVM 38.23
- Support Level
- MODD $0.97
- ADVM $2.64
- Resistance Level
- MODD $1.15
- ADVM $3.64
- Average True Range (ATR)
- MODD 0.09
- ADVM 0.32
- MACD
- MODD 0.01
- ADVM 0.04
- Stochastic Oscillator
- MODD 50.00
- ADVM 17.00
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.